Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Korea ETF (EWY) vs Stryker Corporation (SYK) Price & Performance

iShares MSCI South Korea ETFTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

iShares MSCI South Korea ETF vs Stryker Corporation — how do they compare? iShares MSCI South Korea ETF trades at $175.27, while Stryker Corporation trades at $346.97 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.

EWYSYK
Sector
Broad Market / FactorTechnology
52-Week High
$219.20$394.34
52-Week Low
$71.22$282.58
Market Cap
$133.54B
Enterprise Value
$145.01B
Dividend Yield
1.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Korea ETF

EWY trades at $175.21, up 7.41% over the past 24 hours, showing strong momentum amid volatile South Korean market conditions. The ETF exhibits mixed technical signals with bullish moving averages but neutral oscillators, while support and resistance levels indicate potential consolidation between $166 and $172. Recent news highlights significant volatility in South Korean equities driven by AI and semiconductor sector turbulence, with foreign investors rotating capital away from Asian markets.

The outlook remains cautious as EWY faces headwinds from concentrated exposure to South Korea's volatile semiconductor sector, though government support initiatives and Goldman Sachs' bullish 90% upside projection offer potential catalysts. Key risks include continued foreign capital outflows, leveraged ETF speculation concerns, and dependence on AI-driven market swings that have caused recent sharp declines in major holdings like Samsung and SK Hynix.

Stryker Corporation

Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.

Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK